NCT03766347

Pediatric NMOSD Observational Study

Pediatric Neuromyelitis Optica Spectrum Disorder (NMOSD) 1 Year Observational Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 100 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 2 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to develop a database of pediatric patients in order to study the cause, early detection and best treatment for neuromyelitis optica spectrum disorder (NMOSD) in pediatric patients.

Detailed description

This study is being done to collect information on the natural history of NMOSD in pediatric AQP4-IgG seropositive patients. A major restriction in performing drug studies in pediatric patients with NMOSD is limited information on the course of the disease in these patients. Collecting clinical information over the course of a 1 year observational study would inform on the natural history of the disease in these patients. A repository of pediatric patients with rare diseases can increase knowledge on the natural history of the specific disease, assist in identifying appropriate patients fulfilling specified criteria for drug studies and potentially serve as a control group. Timepoints: Baseline, 3mo, 6mo, 9mo, 12mo (+/- 1 mo for each time point). Baseline data: * Demographics \[age/sex/ethnicity\], * Clinical presentation information including date of initial diagnosis, * Clinical phenotype * Immunotherapy used current and past, * Family history of autoimmune diseases, * Serological data results * Radiologic data as available Self-Report Assessments will be: * Current impairment, as measured by the expanded disability status scale (EDSS) score self-reported using Ratzker (1997) EDSS Self Report form, * Quality of life as measured by the EQ-5D and Varni's (1998) PedsQL over the phone/mail/email. At follow-up visits 3mo, 6mo, 9mo, 12mo (+/- 1 mo for each time point): * Attacks/relapses * Any hospitalizations * Confirm medications and update records if changes Self-Report Assessments at follow-up will be: * Current impairment, as measured by the EDSS score self-reported using Ratzker (1997) EDSS Self Report form, * Quality of life as measured by the EQ-5D and PedsQL over the phone/mail/email.

Conditions

• Neuromyelitis Optica
• NMO Spectrum Disorder

Timeline

• Start date: 2018-02-01
• Primary completion: 2024-04-03
• Completion: 2024-04-03
• First posted: 2018-12-06
• Last updated: 2024-04-10

Locations

1 site across 1 country: United States